Work

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (4419)

Year: 2021

Type: article

Source: Neurology

DOI: 10.1212/wnl.96.15_supplement.4419

Authors: Lana Zhovtis Ryerson, John Foley, Ilya Kister, Gary Cutter, Ryan Metzger, Judith D. Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Ling Jin, Zheng Ren, Nolan Campbell

Institutions: NYU Langone Health, New York University, Rocky Mountain Multiple Sclerosis Clinic, University of Alabama, Biogen (United States)

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3026035733

FWCI: 0.328

Cites:

Cited by: 4

Related to: 10